About this Research Topic
Kidney disease continues to be a major health problem in every nation of the world. According to the World Health Organization, 5 to 10 million people will die each year from kidney diseases. Chronic kidney disease is projected to be the fifth leading cause of mortality globally by 2040. Although current drug therapy has made advances, they are only effective in delaying disease progression. Current treatments cannot reverse the damage to the kidney. It is therefore critical to discover other types of treatment that not only can improve patients’ quality of life but also reverse or/and cure the kidney impairment. Stem cells therapy has established itself as a promising form of treatment for kidney disease. The ability to replicate and differentiate into kidney cells in vitro renders stem cells as a powerful regenerative potential for the damaged kidney. There is increasingly strong evidence from experimental kidney disease studies that stem cell therapy can treat the impaired kidney and attenuate kidney damage while improving the structure and function of glomerular and tubular components. This Research Topic will aim to asses stem cell regeneration strategies in treating kidney diseases: from mechanisms to therapeutics.
We will gladly consider original researches, reviews, and mini reviews covering the topic about stem cell (including embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, endothelial progenitor cells, etc.), or stem cells secretome for kidney diseases for the purpose of regenerating kidney and repairing kidney function.
We welcome topics including but are not limited to the following:
• The role of stem cells in kidney regenerative medicine either in differentiation or paracrine effect in particular kidney cell component or organ as a whole (either in vivo or in vitro).
• Microenvironment or mechanism of the stem cell variability, proliferation, differentiation and function restoration after injury.
• Stem cell tissue engineering on kidney organ construction or organoid.
• Bioinformatics application of stem cell studies on kidney diseases. (Please note: The findings based on data integration should be also validated by observational/experimental data. Descriptive studies and studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic data do not fall within the scope of the journal)
• Stem cell-based therapeutic strategies and mechanism for the kidney function recovery, as well as the translational research or clinical trials.
For review articles, we prefer to have a more unique perspective rather than a summary of previous research.
Note:
Wong CY: holds minority shares in Cytopeutics Sdn. Bhd.
Cheong SK: holds minority shares in Cryocord Sdn Bhd and Cytopeutics Sdn Bhd.
We will gladly consider original researches, reviews, and mini reviews covering the topic about stem cell (including embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, endothelial progenitor cells, etc.), or stem cells secretome for kidney diseases for the purpose of regenerating kidney and repairing kidney function.
We welcome topics including but are not limited to the following:
• The role of stem cells in kidney regenerative medicine either in differentiation or paracrine effect in particular kidney cell component or organ as a whole (either in vivo or in vitro).
• Microenvironment or mechanism of the stem cell variability, proliferation, differentiation and function restoration after injury.
• Stem cell tissue engineering on kidney organ construction or organoid.
• Bioinformatics application of stem cell studies on kidney diseases. (Please note: The findings based on data integration should be also validated by observational/experimental data. Descriptive studies and studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic data do not fall within the scope of the journal)
• Stem cell-based therapeutic strategies and mechanism for the kidney function recovery, as well as the translational research or clinical trials.
For review articles, we prefer to have a more unique perspective rather than a summary of previous research.
Note:
Wong CY: holds minority shares in Cytopeutics Sdn. Bhd.
Cheong SK: holds minority shares in Cryocord Sdn Bhd and Cytopeutics Sdn Bhd.
Keywords: Stem cells, regenerative medicine, kidney disease, microenvironment, mechanism, secretome
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
